Of note this is where a lot or AVR's staff overhead cuts appear to have occurred when we pivoted from the previous IV/product sales company into a product development company a few years ago. It takes a lot of man/woman power to market and sell to big corporations like hospitals/clinics. At least to practitioners it's individual reps who build the relationships, and it's the practitioners that set the device/tool preference that in turn get supplied to hospitals for procedures, not other management non-clinical heads. This is where being the best device in the business gets us into patients - in most specialties I'd say this is a slow process like orthopaedics where all cements/prosthetics are larger comparable.
I really think we are leaps and bounds beyond the competition and cardiologists are pretty savvy. Though I doubt this will be our problem to worry about . Ramble over
- Forums
- ASX - By Stock
- AVR
- Ann: DurAVR First In Human Patient 6 Month Study Follow Up
Ann: DurAVR First In Human Patient 6 Month Study Follow Up, page-45
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.01 |
Change
-0.040(0.21%) |
Mkt cap ! $365.4M |
Open | High | Low | Value | Volume |
$19.00 | $19.01 | $18.77 | $39.53K | 2.091K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $18.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.01 | 3 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 18.520 |
2 | 108 | 18.510 |
1 | 980 | 18.500 |
2 | 290 | 18.250 |
1 | 500 | 18.010 |
Price($) | Vol. | No. |
---|---|---|
19.010 | 3 | 1 |
19.050 | 15 | 1 |
19.100 | 125 | 1 |
19.140 | 63 | 1 |
19.200 | 567 | 1 |
Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |